Skip to content

Precigen PGEN Free cash flow

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
Gilead Sciences logo
Gilead SciencesGILD
$2.43B+46.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$119.68M-29.0%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$119.69M-6.6%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$62.75M+7.3%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Calculated from Precigen’s reported figures.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's free cash flow?
Precigen (PGEN) reported free cash flow of -$44.09M in Q1 2026.
How has Precigen's free cash flow changed year-over-year?
Precigen's free cash flow decreased by 160.1% year-over-year, from -$16.95M to -$44.09M.
What is the long-term trend for Precigen's free cash flow?
Over 4 years (2021 to 2025), Precigen's free cash flow has grown at a 9.3% compound annual growth rate (CAGR), from -$63.02M to -$89.83M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.